08.07.18
Avalon GloboCare Corp. has formed a strategic partnership with Weill Cornell’s cGMP Cellular Therapy Facility and Lab for Advanced Cellular Engineering headed by Dr. Yen-Michael Hsu. The partnership aims to co-develop bio-production and standardization procedures in procurement, storage, processing, clinical study protocols, and bio-banking for Chimeric Antigen Receptor (CAR)-T therapy, in accordance with the Foundation of Accreditation for Cellular Therapy (FACT) and American Association of Blood Banks (AABB) standards. The partnership will enable Avalon GloboCare to implement the resulting laboratory infrastructure and clinical plans in China and the U.S.
This partnership also includes a CAR-T education program to support collaborative research and training programs for scientists and clinicians between Weill Cornell and Hebei Yanda LuDaopei Hospital, which is Avalon GloboCare’s main affiliated clinical facility, as well as the world’s single largest medical institution in CAR-T therapy.
"This strategic partnership will synergize Weill Cornell’s world-class cGMP cellular therapy facility and our immense clinical resources at the LuDaopei hospital network to accelerate innovative CAR-T technology development, standardization in bio-manufacturing process, as well as knowledge exchange in CAR-T and other cellular therapies. Last month, we announced that Avalon formed a new wholly owned U.S. subsidiary, Avactis Biosciences, Inc., which will be focused on accelerating commercial activities related to our proprietary CAR-T technologies. This new subsidiary is designed to integrate and optimize our global scientific and clinical resources, which will be instrumental as we advance this partnership with Weill Cornell," said Dr. David Jin, chief executive officer and president of Avalon GloboCare Corp. and the recently established CAR-T focused subsidiary Avactis Biosciences, Inc. "We are very proud to initiate this endeavor with an overarching goal of integrating premium research and clinical resources worldwide to provide standardized, safer, and more effective CAR-T therapy.”
This partnership also includes a CAR-T education program to support collaborative research and training programs for scientists and clinicians between Weill Cornell and Hebei Yanda LuDaopei Hospital, which is Avalon GloboCare’s main affiliated clinical facility, as well as the world’s single largest medical institution in CAR-T therapy.
"This strategic partnership will synergize Weill Cornell’s world-class cGMP cellular therapy facility and our immense clinical resources at the LuDaopei hospital network to accelerate innovative CAR-T technology development, standardization in bio-manufacturing process, as well as knowledge exchange in CAR-T and other cellular therapies. Last month, we announced that Avalon formed a new wholly owned U.S. subsidiary, Avactis Biosciences, Inc., which will be focused on accelerating commercial activities related to our proprietary CAR-T technologies. This new subsidiary is designed to integrate and optimize our global scientific and clinical resources, which will be instrumental as we advance this partnership with Weill Cornell," said Dr. David Jin, chief executive officer and president of Avalon GloboCare Corp. and the recently established CAR-T focused subsidiary Avactis Biosciences, Inc. "We are very proud to initiate this endeavor with an overarching goal of integrating premium research and clinical resources worldwide to provide standardized, safer, and more effective CAR-T therapy.”
